Modality
Cell Therapy
MOA
EZH2i
Target
ALK
Pathway
Notch
SchizophreniaProstate CaMDS
Development Pipeline
Preclinical
Dec 2024
→ Oct 2029
PreclinicalCurrent
NCT04387781
2,484 pts·Prostate Ca
2024-12→2029-10·Not yet recruiting
2,484 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-10-193.6y awayInterim· Prostate Ca
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Not yet…
Catalysts
Interim
2029-10-19 · 3.6y away
Prostate Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04387781 | Preclinical | Prostate Ca | Not yet recr... | 2484 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Niralucimab | Ionis | Phase 1 | ALK | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 |